{"id":"https://openalex.org/W2970148977","doi":"https://doi.org/10.1016/j.clml.2019.07.220","title":"Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)","display_name":"Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)","publication_year":2019,"publication_date":"2019-08-28","ids":{"openalex":"https://openalex.org/W2970148977","doi":"https://doi.org/10.1016/j.clml.2019.07.220","mag":"2970148977"},"language":"en","primary_location":{"id":"doi:10.1016/j.clml.2019.07.220","doi":"https://doi.org/10.1016/j.clml.2019.07.220","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.clml.2019.07.220","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2650","issn":["2152-2650","2152-2669"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5042260558","display_name":"Kerry Anne Rogers","orcid":"https://orcid.org/0000-0001-5748-7874","observed_orcids":["https://orcid.org/0000-0001-5748-7874"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kerry A. Rogers","raw_affiliation_strings":["The Ohio State University, Columbus, Ohio, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Ohio State University, Columbus, Ohio, United States","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080883357","display_name":"Philip A. Thompson","orcid":"https://orcid.org/0000-0003-2086-6031","observed_orcids":["https://orcid.org/0000-0003-2086-6031"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philip A. Thompson","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, Texas, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, Texas, United States","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026842309","display_name":"John Nathan Allan","orcid":"https://orcid.org/0000-0002-2088-0899","observed_orcids":["https://orcid.org/0000-0002-2088-0899"]},"institutions":[{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John N. Allan","raw_affiliation_strings":["Weill Cornell Medicine, New York, New York, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Weill Cornell Medicine, New York, New York, United States","institution_ids":["https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082720713","display_name":"Morton Coleman","orcid":"https://orcid.org/0000-0002-8516-2513","observed_orcids":["https://orcid.org/0000-0002-8516-2513"]},"institutions":[{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Morton Coleman","raw_affiliation_strings":["Weill Cornell Medicine, New York, New York, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Weill Cornell Medicine, New York, New York, United States","institution_ids":["https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013007045","display_name":"Jeff Porter Sharman","orcid":"https://orcid.org/0000-0001-5611-6115","observed_orcids":["https://orcid.org/0000-0001-5611-6115"]},"institutions":[{"id":"https://openalex.org/I4210148213","display_name":"Willamette Valley Cancer Institute and Research Center","ror":"https://ror.org/05jr8e497","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210148213"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeff P. Sharman","raw_affiliation_strings":["Willamette Valley Cancer Institute, Eugene, Oregon, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Willamette Valley Cancer Institute, Eugene, Oregon, United States","institution_ids":["https://openalex.org/I4210148213"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082606841","display_name":"Bruce D. Cheson","orcid":"https://orcid.org/0000-0001-9255-7655","observed_orcids":["https://orcid.org/0000-0001-9255-7655","https://orcid.org/0000-0002-6246-4308"]},"institutions":[{"id":"https://openalex.org/I184565670","display_name":"Georgetown University","ror":"https://ror.org/05vzafd60","country_code":"US","type":"education","lineage":["https://openalex.org/I184565670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bruce D. Cheson","raw_affiliation_strings":["Georgetown University Hospital, Washington, D.C., United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Georgetown University Hospital, Washington, D.C., United States","institution_ids":["https://openalex.org/I184565670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029736763","display_name":"Raquel E. Izumi","orcid":"https://orcid.org/0000-0002-0895-2597","observed_orcids":["https://orcid.org/0000-0002-0895-2597"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Raquel Izumi","raw_affiliation_strings":["Acerta Pharma, South San Francisco, California, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acerta Pharma, South San Francisco, California, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021503872","display_name":"Melanie M. Frigault","orcid":"https://orcid.org/0009-0002-8525-4239","observed_orcids":["https://orcid.org/0009-0002-8525-4239"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Melanie M. Frigault","raw_affiliation_strings":["Acerta Pharma, South San Francisco, California, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acerta Pharma, South San Francisco, California, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029812588","display_name":"Cheng Seok Quah","orcid":"https://orcid.org/0009-0000-4250-7828","observed_orcids":["https://orcid.org/0009-0000-4250-7828"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cheng Quah","raw_affiliation_strings":["Acerta Pharma, South San Francisco, California, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acerta Pharma, South San Francisco, California, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047195069","display_name":"Rakesh Kumar Raman","orcid":"https://orcid.org/0000-0003-2229-6642","observed_orcids":["https://orcid.org/0000-0003-2229-6642"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rakesh K. Raman","raw_affiliation_strings":["Acerta Pharma, South San Francisco, California, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acerta Pharma, South San Francisco, California, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087424125","display_name":"Min Hui Wang","orcid":"https://orcid.org/0000-0002-2073-5392","observed_orcids":["https://orcid.org/0000-0002-2073-5392"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Min Hui Wang","raw_affiliation_strings":["Acerta Pharma, South San Francisco, California, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acerta Pharma, South San Francisco, California, United States","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036828560","display_name":"Thomas J. Kipps","orcid":"https://orcid.org/0000-0002-0064-4549","observed_orcids":["https://orcid.org/0000-0002-0064-4549"]},"institutions":[{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas J. Kipps","raw_affiliation_strings":["UC San Diego Moores Cancer Center, San Diego, California, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UC San Diego Moores Cancer Center, San Diego, California, United States","institution_ids":["https://openalex.org/I4390039236"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":1900,"currency":"USD","value_usd":1900},"apc_paid":null,"fwci":0.185,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.54508514,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"19","issue":null,"first_page":"S282","last_page":"S283"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acalabrutinib","display_name":"acalabrutinib","score":1.0},{"id":"https://openalex.org/keywords/relapsed-refractory-chronic-lymphocytic-leukemia","display_name":"relapsed/refractory chronic lymphocytic leukemia","score":0.9919999837875366},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.9509999752044678},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.9049999713897705},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.5709999799728394}],"concepts":[{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.9748036861419678},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.8828666806221008},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.777656078338623},{"id":"https://openalex.org/C90059517","wikidata":"https://www.wikidata.org/wiki/Q423572","display_name":"Bruton's tyrosine kinase","level":4,"score":0.7486971020698547},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6620972156524658},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5229566693305969},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4851166009902954},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4633738398551941},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4112013876438141},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.38604870438575745},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.3576008379459381},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.07928231358528137},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.07533520460128784},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.clml.2019.07.220","doi":"https://doi.org/10.1016/j.clml.2019.07.220","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.clml.2019.07.220","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2650","issn":["2152-2650","2152-2669"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2953901052","https://openalex.org/W2950737717","https://openalex.org/W2952654720","https://openalex.org/W2945468305","https://openalex.org/W3138884962","https://openalex.org/W2980218067","https://openalex.org/W3169967795","https://openalex.org/W2983802128","https://openalex.org/W3185734192","https://openalex.org/W2557897880"],"abstract_inverted_index":null,"counts_by_year":[{"year":2022,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-09-05T00:00:00"}